Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00708500
First received: June 27, 2008
Last updated: August 12, 2014
Last verified: August 2014

June 27, 2008
August 12, 2014
August 2008
April 2010   (final data collection date for primary outcome measure)
Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population. [ Time Frame: At Follow-up Week 24 ] [ Designated as safety issue: No ]
SVR is defined as undetectable plasma hepatitis C virus RNA (HCV-RNA) at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with chronic hepatitis C (CHC) genotype 1 who failed prior treatment.
Sustained virologic response (SVR), defined as undetectable plasma HCV-RNA at Follow-up Week 24, after treatment with boceprevir and PegIntron plus ribavirin or PegIntron plus ribavirin alone in subjects with CHC genotype 1 who failed prior treatment. [ Time Frame: At Follow-up Week 24 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00708500 on ClinicalTrials.gov Archive Site
  • Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population. [ Time Frame: At Follow-up Week 24 ] [ Designated as safety issue: No ]

    SVR is defined as undetectable plasma HCV-RNA at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with CHC genotype 1 who failed prior treatment.

    This key secondary efficacy endpoint was added as per the second protocol amendment on 02 DEC 2009.

  • Number of Participants With Early Virologic Response. [ Time Frame: At Week 2, 4, 8, or 12 ] [ Designated as safety issue: No ]
    Having undetectable HCV-RNA at Week 2, 4, 8, or 12 was considered Early Virologic Response.
  • Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization. [ Time Frame: At Follow-up Week 12 and at 72 weeks after randomization ] [ Designated as safety issue: No ]
  • Proportion of subjects with early virologic response (undetectable HCV-RNA at Week 2, 4, 8, or 12) who achieved SVR. [ Time Frame: At Week 2, 4, 8, or 12 ] [ Designated as safety issue: No ]
  • Proportions of subjects with undetectable HCV-RNA at Follow-up Week 12 and at 72 weeks after randomization. [ Time Frame: At Follow-up Week 12 and at 72 weeks after randomization ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin

This study involves treatment with boceprevir or placebo in combination with pegylated interferon alfa-2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) in adult subjects with chronic hepatitis C (CHC) genotype 1 who demonstrated interferon responsiveness (a decrease in hepatitis C virus RNA [HCV-RNA] viral load >=2 log10 by Week 12 or undetectable HCV-RNA at end of treatment) but who failed to achieve sustained virologic response (SVR) on prior treatment with any combination therapy of peginterferon alpha and RBV. This trial includes three arms, one control arm (PEG2b + RBV for 48 weeks) and two experimental arms (PEG2b + RBV + boceprevir). One of the experimental arms, Arm 3, consists of treatment with all three drugs for 44 weeks after the lead-in. The other experimental arm, Arm 2, consists of all three drugs for 32 weeks after the lead-in. Participants in Arm 2 who were undetectable for HCV-RNA at Treatment Week 8 will complete treatment at that point. Those who were not undetectable for HCV-RNA at Treatment Week 8 will receive an additional 12 weeks of PEG2b + RBV + boceprevir placebo. It is hypothesized that the addition of a third active anti-HCV drug may lead to more rapid viral response than therapy with two drugs, and therefore, the addition of boceprevir to PEG2b plus RBV therapy after a 4-week lead-in period may allow for both increased rates of SVR and shorter treatment durations (in some populations) than treatment with peginterferon plus RBV alone.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Hepatitis C, Chronic
  • Drug: Boceprevir (SCH 503034)
    Boceprevir, 200 mg capsules, 800 mg TID PO
  • Biological: Pegylated interferon alfa-2b (SCH 54031)
    PEG2b 1.5 μg/kg/week subcutaneously (SC)
    Other Names:
    • PegIntron
    • PEG2b
  • Drug: Ribavirin (SCH 18908)
    Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
    Other Names:
    • Rebetol
    • RBV
  • Drug: Boceprevir placebo
    Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
  • Placebo Comparator: Placebo+PEG2b+RBV, x 44 weeks
    Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
    Interventions:
    • Biological: Pegylated interferon alfa-2b (SCH 54031)
    • Drug: Ribavirin (SCH 18908)
    • Drug: Boceprevir placebo
  • Experimental: Boceprevir+PEG2b+RBV, Response Guided Therapy

    Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.

    PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:

    • 36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
    • 48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.
    Interventions:
    • Drug: Boceprevir (SCH 503034)
    • Biological: Pegylated interferon alfa-2b (SCH 54031)
    • Drug: Ribavirin (SCH 18908)
    • Drug: Boceprevir placebo
  • Experimental: Boceprevir+PEG2b+RBV, x 44 weeks
    Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
    Interventions:
    • Drug: Boceprevir (SCH 503034)
    • Biological: Pegylated interferon alfa-2b (SCH 54031)
    • Drug: Ribavirin (SCH 18908)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
404
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Qualifying regimen defined as pegylated interferon alfa-2a plus ribavirin or pegylated interferon alfa-2b plus ribavirin for a minimum of 12 weeks.
  • During qualifying regimen, participants must have either a documented undetectable HCV-RNA within 30 days of end of treatment (EOT) and a subsequent detectable HCV-RNA during follow-up or a documented decline in HCV-RNA by >=2 log10 by Treatment Week 12
  • Previously documented CHC genotype 1 infection.
  • Liver biopsy with histology consistent with CHC and no other etiology.
  • Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the Screening Visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC).
  • Participants participating in Schering-Plough Research Institute (SPRI) maintenance protocols P02570 (NCT00049842) or P02569 (NCT00048724) must have completed the study to be eligible for this protocol.
  • Participants must be >=18 years of age.
  • Participants must weigh between 40 kg and 125 kg.
  • Participants and participant's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations.
  • Participants must be willing to give written informed consent.

Exclusion Criteria:

  • Coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B Surface Antigen [HBsAg] positive).
  • Discontinuation of previous interferon or ribavirin regimen for an adverse event (AE) considered by the investigator to be possibly or probably related to ribavirin and/or interferon.
  • Treatment with ribavirin within 90 days and any interferon-alpha within 1 month of Screening.
  • Treatment for hepatitis C with any investigational medication. Prior treatment with herbal remedies with known hepatotoxicity.
  • Treatment with any investigational drug within 30 days of the randomization visit.
  • Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial.
  • Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.
  • Diabetic and/or hypertensive participants with clinically significant ocular examination findings.
  • Pre-existing psychiatric conditions.
  • Clinical diagnosis of substance abuse of the specified drugs within the specified timeframes
  • Any known pre-existing medical condition that could interfere with the participant's participation in and completion of the study.
  • Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of the skin). Participants under evaluation for malignancy are not eligible.
  • Participants who are pregnant or nursing. Participants who intend to become pregnant during the study period. Male participants with partners who are, or intend to become, pregnant during the study period.
  • Any other condition which, in the opinion of a physician, would make the participant unsuitable for enrollment or could interfere with the participant participating in and completing the study.
  • Participants who are part of the site personnel directly involved with this study.
  • Participants who are family members of the investigational study staff.
  • Participants who had life-threatening serious adverse event (SAE) during screening period.
  • Protocol-specified hematologic, biochemical, and serologic criteria: Hemoglobin <12 g/dL for females and <13 g/dL for males; Neutrophils <1500/mm^3 (Blacks: <1200/mm^3); Platelets <100,000/mm^3; Direct bilirubin >1.5 x upper limit of normal (ULN).
  • Serum albumin <lower limit of normal (LLN)
  • Thyroid-stimulating hormone (TSH) >1.2 x ULN or <0.8 x LLN of laboratory reference range, with certain exceptions.
  • Serum creatinine >ULN of the laboratory reference.
  • Protocol-specified serum glucose concentrations.
  • Protocol-specified alpha fetoprotein range.
  • Prothrombin Time/Partial Thromboplastin Time (PT/PTT) values >10% above laboratory reference range.
  • Anti-nuclear antibodies (ANA) >1:320.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00708500
P05101, 2007-005151-42
Yes
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP